Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families - PubMed (original) (raw)
. 2002 Jun 15;62(12):3485-92.
Affiliations
- PMID: 12067992
Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families
Siobhan S Wahlberg et al. Cancer Res. 2002.
Abstract
Forty-eight hereditary nonpolyposis colorectal carcinoma (HNPCC) families for which a tumor sample was available were evaluated for the presence of germ-line mutations in MSH2 and MLH1, tumor microsatellite instability (MSI), and where possible, expression of MSH2 and MLH1 in tumors by immunohistochemistry. Fourteen of 48 of the families had a germ-line mutation in either MSH2 or MLH1 that could be detected by genomic DNA sequencing, and 28 of 48 of the families had MSI-H tumors. Four additional families showed loss of expression of MSH2, and one additional family showed loss of expression of MLH1 but did not have germ-line mutations in MSH2 or MLH1 that could be detected by DNA sequencing. MSI-H, as defined using the National Cancer Institute recommended five-microsatellite panel, had a 100% sensitivity for identifying samples having MSH2 or MLH1 mutations or loss of expression. In contrast, loss of MSH2 and MLH1 expression did not identify all samples having germ-line mutations in MSH2 or MLH1, because in five cases, a mutant protein product was expressed that could be detected by IHC. A combination of the Bethesda criteria for HNPCC and an MSI-H phenotype defined the smallest number of cases having all of the germ-line MSH2 and MLH1 mutations that could be detected by DNA sequencing.
Similar articles
- Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
Piñol V, Castells A, Andreu M, Castellví-Bel S, Alenda C, Llor X, Xicola RM, Rodríguez-Moranta F, Payá A, Jover R, Bessa X; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Piñol V, et al. JAMA. 2005 Apr 27;293(16):1986-94. doi: 10.1001/jama.293.16.1986. JAMA. 2005. PMID: 15855432 - Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
Caldés T, Godino J, Sanchez A, Corbacho C, De la Hoya M, Lopez Asenjo J, Saez C, Sanz J, Benito M, Ramon Y Cajal S, Diaz-Rubio E. Caldés T, et al. Oncol Rep. 2004 Sep;12(3):621-9. Oncol Rep. 2004. PMID: 15289847 - Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability.
Lanza G, Gafà R, Maestri I, Santini A, Matteuzzi M, Cavazzini L. Lanza G, et al. Mod Pathol. 2002 Jul;15(7):741-9. doi: 10.1097/01.MP.0000018979.68686.B2. Mod Pathol. 2002. PMID: 12118112 - The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome.
Lucci-Cordisco E, Boccuto L, Neri G, Genuardi M. Lucci-Cordisco E, et al. Cancer Biomark. 2006;2(1-2):11-27. doi: 10.3233/cbm-2006-21-203. Cancer Biomark. 2006. PMID: 17192056 Review. - Carcinogenesis in the GI tract: from morphology to genetics and back again.
Redston M. Redston M. Mod Pathol. 2001 Mar;14(3):236-45. doi: 10.1038/modpathol.3880292. Mod Pathol. 2001. PMID: 11266532 Review.
Cited by
- Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition.
Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T, Igarashi A, Ikeda M, Kadowaki S, Kajiyama H, Kato M, Kenmotsu H, Kodera Y, Komine K, Koyama T, Maeda O, Miyachi M, Nishihara H, Nishiyama H, Ohga S, Okamoto W, Oki E, Ono S, Sanada M, Sekine I, Takano T, Tao K, Terashima K, Tsuchihara K, Yatabe Y, Yoshino T, Baba E. Mishima S, et al. Int J Clin Oncol. 2023 Oct;28(10):1237-1258. doi: 10.1007/s10147-023-02397-9. Epub 2023 Aug 20. Int J Clin Oncol. 2023. PMID: 37599324 Free PMC article. - Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors.
Rasmussen M, Sowter P, Gallon R, Durhuus JA, Hayes C, Andersen O, Nilbert M, Schejbel L, Høgdall E, Santibanez-Koref M, Jackson MS, Burn J, Therkildsen C. Rasmussen M, et al. Front Oncol. 2023 Apr 18;13:1147591. doi: 10.3389/fonc.2023.1147591. eCollection 2023. Front Oncol. 2023. PMID: 37143941 Free PMC article. - Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies.
Moshawih S, Lim AF, Ardianto C, Goh KW, Kifli N, Goh HP, Jarrar Q, Ming LC. Moshawih S, et al. Biomolecules. 2022 Jun 23;12(7):878. doi: 10.3390/biom12070878. Biomolecules. 2022. PMID: 35883434 Free PMC article. Review. - Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.
Leclerc J, Vermaut C, Buisine MP. Leclerc J, et al. Cancers (Basel). 2021 Jan 26;13(3):467. doi: 10.3390/cancers13030467. Cancers (Basel). 2021. PMID: 33530449 Free PMC article. Review. - Unexpected expression of mismatch repair protein is more commonly seen with pathogenic missense than with other mutations in Lynch syndrome.
Chen W, Hampel H, Pearlman R, Jones D, Zhao W, Alsomali M, Knight D, Frankel WL. Chen W, et al. Hum Pathol. 2020 Sep;103:34-41. doi: 10.1016/j.humpath.2020.07.001. Epub 2020 Jul 8. Hum Pathol. 2020. PMID: 32652087 Free PMC article.